James T. Parsons Insider Profile
11 Followers
James T. Parsons, Director at Oncolytics Biotech, holds 41.85K shares in Oncolytics Biotech (Ticker: ONCY), holds 97.95K shares in Diamedica Therapeutics (Ticker: DMAC), holds 0.00 shares in Trillium Therapeutics (Ticker: ~TRIL). Most recently, James T. Parsons Bought ― shares of Oncolytics Biotech on Mar 13, 2026 for an estimated value of $10.30K.
James T. Parsons has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that James T. Parsons holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by James T. Parsons
James T. Parsons's Trading History
Oncolytics Biotech
Mar 13, 2026
Director
Informative Buy
10.30K
$35.28K
Diamedica Therapeutics
Jan 06, 2026
Director
Uninformative Buy
85.00K
$661.16K
Trillium Therapeutics
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see James T. Parsons's performance on stock
You May Also Like
James T. Parsons insider profile FAQ
What is the percentage of profitable transactions made by James T. Parsons?
The percentage of profitable transactions made by James T. Parsons is ―.
What is the average return per transaction made by James T. Parsons?
The average return per transaction made by James T. Parsons is ―.
What stocks does James T. Parsons hold?
James T. Parsons holds: ONCY, DMAC, ~TRIL stocks.
What was James T. Parsons’s latest transaction?
James T. Parsons latest transaction was an Informative Buy of $10.30K.
What was James T. Parsons's most profitable transaction?
James T. Parsons’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is James T. Parsons's role in Oncolytics Biotech?
James T. Parsons's role in Oncolytics Biotech is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.